- Investing.com
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Strategic Shift | Explore Kenvue's "Extraordinary Powers" strategy, aimed at revitalizing underperforming segments and driving operational success across the business |
Financial Outlook | Analysts project EPS of $1.14 for FY1 and $1.21-$1.22 for FY2, with price targets ranging from $21 to $29, reflecting diverse market expectations |
Segment Performance | Delve into Kenvue's mixed segment results: Self Care and Essential Health show resilience, while Skin Health & Beauty faces challenges and potential recovery |
Market Challenges | Learn how Kenvue navigates industry headwinds, including tariff impacts and shifting consumer preferences, while maintaining a strong competitive position |
Metrics to compare | KVUE | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipKVUEPeersSector | |
---|---|---|---|---|
P/E Ratio | 21.4x | 25.4x | 12.2x | |
PEG Ratio | 0.74 | 0.41 | 0.03 | |
Price/Book | 2.8x | 2.3x | 1.5x | |
Price / LTM Sales | 2.0x | 1.8x | 1.0x | |
Upside (Analyst Target) | 39.2% | 97.5% | 19.0% | |
Fair Value Upside | Unlock | 11.3% | 10.3% | Unlock |